Skip to main content
SpringerLink
Log in

Chemotherapy and Novel Systemic Approaches in the Treatment of Metastatic Castration Resistant Prostate Cancer

  • Chapter
  • First Online:
Prostate Cancer: A Comprehensive Perspective

  • 2937 Accesses

Abstract

This chapter serves as a review of the current standard systemic treatment options available for metastatic castration resistant prostate cancer as well as the concepts and rationale behind the various targeted agents that are currently in clinical testing with an emphasis on those agents that have entered into later phase clinical trials. In particular, agents targeting androgen receptor activation and local steroidogenesis, the insulin-like growth factor pathway, chaperone proteins, angiogenesis, RANK ligand, endothelin receptors, Src family kinases, and immunomodulatory agents will be reviewed. Novel agents that have come to interest based upon preclinical rationale and early-phase trial data will also be reviewed including multi-targeted tyrosine kinase inhibitors, agents affecting signal transduction pathways, and novel cytotoxics.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 229.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.

    PubMed  Google Scholar 

  2. Catalona WJ, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol. 1998;160(6 Pt 2):2428–34.

    PubMed  CAS  Google Scholar 

  3. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. J Am Med Assoc. 1998;280:969–74.

    Google Scholar 

  4. Gerber GS, Thisted RA, Scardino PT, Frohmuller HG, Schroeder FH, Paulson DF, et al. Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA. 1996;276(8):615–9.

    PubMed  CAS  Google Scholar 

  5. Giberti C, Chiono L, Gallo F, Schenone M, Gastaldi E. Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic cancer: a prospective study. World J Urol. 2009;27(5):607–12.

    PubMed  CAS  Google Scholar 

  6. Kattan MW, Zelefsky MJ, Kupelian PA, Cho D, Scardino PT, Fuks Z, et al. Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. J Clin Oncol. 2003;21(24):4568–71.

    PubMed  Google Scholar 

  7. Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, et al. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 2003;57(4):915–28.

    PubMed  Google Scholar 

  8. Kupelian PA, Katcher J, Levin HS, Klein EA. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys. 1997;37(5):1043–52.

    PubMed  CAS  Google Scholar 

  9. Parker CC, Norman AR, Huddart RA, Horwich A, Dearnaley DP. Pre-treatment nomogram for biochemical control after neoadjuvant androgen deprivation and radical radiotherapy for clinically localised prostate cancer. Br J Cancer. 2002;86(5):686–91.

    PubMed  CAS  Google Scholar 

  10. Shipley WU, Thames HD, Sandler HM, Hanks GE, Zietman AL, Perez CA, et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA. 1999;281(17):1598–604.

    PubMed  CAS  Google Scholar 

  11. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol. 1994;152(5 Pt 2):1831–6.

    PubMed  CAS  Google Scholar 

  12. Zelefsky MJ, Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys. 2007;67(2):327–33.

    PubMed  Google Scholar 

  13. Zincke H, Bergstralh EJ, Blute ML, Myers RP, Barrett DM, Lieber MM, et al. Radical prostatectomy for clinically localized prostate cancer: long-term results of 1,143 patients from a single institution. J Clin Oncol. 1994;12(11):2254–63.

    PubMed  CAS  Google Scholar 

  14. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321(7):419–24.

    PubMed  CAS  Google Scholar 

  15. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294(2):238–44.

    PubMed  CAS  Google Scholar 

  16. Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med. 2004;351:1488–90.

    PubMed  CAS  Google Scholar 

  17. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;1:34–5.

    PubMed  CAS  Google Scholar 

  18. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003;21(7):1232–7.

    PubMed  Google Scholar 

  19. Halabi S, Vogelzang NJ, Ou SS, Owzar K, Archer L, Small EJ. Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. J Clin Oncol. 2009;27(17): 2766–71.

    PubMed  Google Scholar 

  20. De Bono JS, Attard G, Reid AH, Parker C, Dowsett M, Mollife R, et al. Anti-tumor activity of abiraterone acetate (AA), a CYP17 inhibitor of androgen synthesis, in chemotherapy naive and docetaxel pre-treated castration resistant prostate cancer (CRPC). J Clin Oncol. 2008;26:abstract 5005.

    Google Scholar 

  21. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14(19):6302–9.

    PubMed  Google Scholar 

  22. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.

    PubMed  CAS  Google Scholar 

  23. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005.

    PubMed  Google Scholar 

  24. Parker C, Heinrich D, O’Sullivan JM. Overall survival benefit of radium-223 chloride (alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant Prostate cancer (CRPC): a phase III randomised trial (ALSYMPCA). ESMO 2011 annual conference, 2011.

    Google Scholar 

  25. Kantoff PW, Higano CS, Neal MD, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22.

    PubMed  CAS  Google Scholar 

  26. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999;17(8):2506–13.

    PubMed  CAS  Google Scholar 

  27. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–54.

    PubMed  Google Scholar 

  28. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813–22.

    PubMed  CAS  Google Scholar 

  29. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22.

    PubMed  CAS  Google Scholar 

  30. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756–64.

    PubMed  CAS  Google Scholar 

  31. Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol. 2002;168(6):2439–43.

    PubMed  CAS  Google Scholar 

  32. Hahn NM, Marsh S, Fisher W, Langdon R, Zon R, Browning M, et al. Hoosier oncology group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis. Clin Cancer Res. 2006;12(20 Pt 1):6094–9.

    PubMed  CAS  Google Scholar 

  33. Ferrero JM, Chamorey E, Oudard S, Dides S, Lesbats G, Cavaglione G, et al. Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer. Cancer. 2006;107(4):738–45.

    PubMed  CAS  Google Scholar 

  34. Petrioli R, Paolelli L, Francini E, Manganelli A, Salvestrini F, Francini G. Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer. Urology. 2007;69(1):142–6.

    PubMed  Google Scholar 

  35. Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20.

    PubMed  CAS  Google Scholar 

  36. Machiels JP, Mazzeo F, Clausse M, Filleul B, Marcelis L, Honhon B, et al. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2008;26(32):5261–8.

    PubMed  CAS  Google Scholar 

  37. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT investigators. J Clin Oncol. 2007;25(6):669–74.

    PubMed  CAS  Google Scholar 

  38. Scher HI, Chi KN, DeWit, et al. Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (pts) with progressive castration-resistant prostate cancer(CRPC): results from the phase III ASCENT2 trial. J Clin Oncol. 2010;82(s344):abstract 4509.

    Google Scholar 

  39. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–54.

    PubMed  Google Scholar 

  40. Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, Ferrero JM, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol. 2009;27(32):5431–8.

    PubMed  CAS  Google Scholar 

  41. Hussain M, Tangen CM, Lara Jr PN, Vaishampayan UN, Petrylak DP, Colevas AD, et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol. 2005;23(34):8724–9.

    PubMed  Google Scholar 

  42. Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G, Gross M, Hutcheon D, Small EJ. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer. 2007;110(3):556–63.

    PubMed  CAS  Google Scholar 

  43. Chi KN, Beardsley EK, Venner PM, et al. A phase II study of patupilone in patients with metastatic hormone refractory prostate cancer (HRPC) who have progressed after docetaxel. J Clin Oncol. 2008;26(15s):asbtract 5166.

    Google Scholar 

  44. Knudsen KE, Arden KC, Cavenee WK. Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. J Biol Chem. 1998;273(32):20213–22.

    PubMed  CAS  Google Scholar 

  45. Xu Y, Chen SY, Ross KN, Balk SP. Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. Cancer Res. 2006;66(15):7783–92.

    PubMed  CAS  Google Scholar 

  46. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644–8.

    PubMed  CAS  Google Scholar 

  47. Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol. 2007;31(6):882–8.

    PubMed  Google Scholar 

  48. Cerveira N, Ribeiro FR, Peixoto A, Costa V, Henrique R, Jeronimo C, et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia. 2006;8(10):826–32.

    PubMed  CAS  Google Scholar 

  49. van der Kwast TH, Schalken J, Ruizeveld de Winter JA, van Vroonhoven CC, Mulder E, Boersma W, et al. Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer. 1991;48(2):189–93.

    PubMed  Google Scholar 

  50. Ruizeveld de Winter JA, Janssen PJ, Sleddens HM, Verleun-Mooijman MC, Trapman J, Brinkmann AO, et al. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol. 1994;144(4):735–46.

    PubMed  CAS  Google Scholar 

  51. Mohler JL, Gregory CW, Ford 3rd OH, Kim D, Weaver CM, Petrusz P, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res. 2004;10:440–8.

    PubMed  CAS  Google Scholar 

  52. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med. 1995;332(21):1393–8.

    PubMed  CAS  Google Scholar 

  53. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol. 2004;164:217–27.

    PubMed  CAS  Google Scholar 

  54. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006;66:2815–25.

    PubMed  CAS  Google Scholar 

  55. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet. 1995;9(4):401–6.

    PubMed  CAS  Google Scholar 

  56. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 1997;57(2):314–9.

    PubMed  CAS  Google Scholar 

  57. Page ST, Lin DW, Mostaghel EA, Hess DL, True LD, Amory JK, et al. Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab. 2006;91(10):3850–6.

    PubMed  CAS  Google Scholar 

  58. Geller J, Albert J. Effects of castration compared with total androgen blockade on tissue dihydrotestosterone (DHT) concentration in benign prostatic hyperplasia (BPH). Urol Res. 1987;15(3):151–3.

    PubMed  CAS  Google Scholar 

  59. Nishiyama T, Hashimoto Y, Takahashi K. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res. 2004;10(21):7121–6.

    PubMed  CAS  Google Scholar 

  60. Mizokami A, Koh E, Fujita H, Maeda Y, Egawa M, Koshida K, et al. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res. 2004;64(2):765–71.

    PubMed  CAS  Google Scholar 

  61. Belanger B, Belanger A, Labrie F, Dupont A, Cusan L, Monfette G. Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men. J Steroid Biochem. 1989;32(5):695–8.

    PubMed  CAS  Google Scholar 

  62. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68(11):4447–54.

    PubMed  CAS  Google Scholar 

  63. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 2008;68:6407–15.

    PubMed  CAS  Google Scholar 

  64. Hofland J, van Weerden WM, Dits NF, Steenbergen J, van Leenders GJ, Jenster G, et al. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res. 2010;70(3):1256–64.

    PubMed  CAS  Google Scholar 

  65. Steinberg J, Oyasu R, Lang S, Sintich S, Rademaker A, Lee C, et al. Intracellular levels of SGP-2 (clusterin) correlate with tumor grade in prostate cancer. Clin Cancer Res. 1997;3(10):1707–11.

    PubMed  CAS  Google Scholar 

  66. Lin HK, Steckelbroeck S, Fung KM, Jones AN, Penning TM. Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate. Steroids. 2004;69(13–14):795–801.

    PubMed  CAS  Google Scholar 

  67. El-Alfy M, Luu-The V, Huang XF, Berger L, Labrie F, Pelletier G. Localization of type 5 17beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology. 1999;140(3):1481–91.

    PubMed  CAS  Google Scholar 

  68. Dufort I, Rheault P, Huang XF, Soucy P, Luu-The V. Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase. Endocrinology. 1999;140(2):568–74.

    PubMed  CAS  Google Scholar 

  69. Penning TM, Burczynski ME, Jez JM, Hung CF, Lin HK, Ma H, et al. Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J. 2000;351(Pt 1):67–77.

    PubMed  CAS  Google Scholar 

  70. Attar RM, Jeur-Kunkel M, Balog A, Cvijic ME, Dell-John J, et al. Discovery of BMS-641988, a novel and potent inhibitor of androgen receptor signaling for the treatment of prostate cancer. Cancer Res. 2009;69(16):6522–30.

    PubMed  CAS  Google Scholar 

  71. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26:4563–71.

    PubMed  CAS  Google Scholar 

  72. Ryan C, Efstathios E, Smith M, Taplin M, Bublet G, et al. Phase II multicenter study of chemotherapy (chemo)-naive castration-resistant prostate cancer (CRPC) not exposed to ketoconazole (keto), treated with abiraterone acetate (AA) plus prednisone. J Clin Oncol. 2009;27:abstract 5046.

    Google Scholar 

  73. Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol. 2010;28(9):1489–95.

    PubMed  CAS  Google Scholar 

  74. Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-­resistant prostate cancer. J Clin Oncol. 2010;28(9):1496–501.

    PubMed  CAS  Google Scholar 

  75. Dreicer R, Agus DB, MacVicar GR, et al. Safety, pharmakokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostate cancer: a phase I/II, open-label study. 2010 ASCO annual meeting. 2010:abstract #3084.

    Google Scholar 

  76. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet. 2010;375(9724):1437–46.

    PubMed  CAS  Google Scholar 

  77. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. J Am Med Assoc. 2004;292:490–5.

    CAS  Google Scholar 

  78. Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, Rabbani SA. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer. 2006;107:289–98.

    PubMed  CAS  Google Scholar 

  79. Brown JM, Vessella RL, Kostenuik PJ, Dunstan CR, Lange PH, Corey E. Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin Cancer Res. 2001;7:2977–83.

    PubMed  CAS  Google Scholar 

  80. Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab. 2008;93:2149–57.

    PubMed  CAS  Google Scholar 

  81. Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008;26:4875–82.

    PubMed  CAS  Google Scholar 

  82. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995;1:944–9.

    PubMed  CAS  Google Scholar 

  83. Carducci MA, Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res. 2006;12:6296–300.

    Google Scholar 

  84. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol. 2003;21:679–89.

    PubMed  CAS  Google Scholar 

  85. Carducci MA, Saad F, Abrahamsson PA, Dearnaley DP, Schulman CC, North SA, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer. 2007;110:1959–66.

    PubMed  CAS  Google Scholar 

  86. Nelson JB, Love W, Chin JL, Saad F, Schulman CC, Sleep DJ, et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer. 2008;113:2478–87.

    PubMed  CAS  Google Scholar 

  87. James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol. 2009;55(5):1112–23. Epub 2008 Nov 29.

    PubMed  CAS  Google Scholar 

  88. Tatarov O, Mitchell TJ, Seywright M, Leung HY, Brunton VG, Edwards J. Src family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res. 2009;15(10):3540–9.

    PubMed  CAS  Google Scholar 

  89. Fizazi K. The role of Src in prostate cancer. Ann Oncol. 2007;18:1765–73.

    PubMed  CAS  Google Scholar 

  90. Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res. 2005;65:9185–9.

    PubMed  CAS  Google Scholar 

  91. Yu EY, Wilding G, Posadas E, Gross M, Culine S, Massard C, et al. Dasatinib in patients with hormone-refractory progressive prostate cancer: a phase II study. J Clin Oncol. 2008;26:abstract 5156.

    Google Scholar 

  92. Yu E, Massard C, Gross M, Wilding G, Posadas E, Culine S, et al. A phase II study of once-daily dasatinib for patients with castration-resistant prostate cancer (CRPC) (CA180085). Gentiourinary cancers symposium (ASCO, ASTRO, SUO). 2009:abstract 165.

    Google Scholar 

  93. Araujo J, Armstrong AJ, Braud EL, Posadas E, Lonberg E, et al. Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: a phase I/II study. J Clin Oncol. 2009;27:abstract 5061.

    Google Scholar 

  94. Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM, Ell PJ, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol. 1998;16(4):1574–81.

    PubMed  CAS  Google Scholar 

  95. Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, Coleman RE, et al. Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004;63(5):940–5.

    PubMed  Google Scholar 

  96. Eisenberger MA, Lin J, Sinibaldi J, Carducci MA, Denmeade S, et al. Phase I trial with a combination of docetaxel and 153Sm-EDTMP in patients with castration-resistant prostate cancer. J Clin Oncol. 2009;27:abstract 5155.

    Google Scholar 

  97. Fizazi K, Beuzeboc P, Lumbroso J, Haddad V, Massard C, et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol. 2009;27:2429–35.

    PubMed  CAS  Google Scholar 

  98. Morris MJ, Pandit-Taskar N, Stephenson RD, Hong C, Slovin SF, et al. Phase I/II study of docetaxel and 153-sm for castrate metastatic prostate cancer: summary of dose-escalation cohorts and first report of the expansion cohort. J Clin Oncol. 2009;27:abstract 5057.

    Google Scholar 

  99. Bellmunt J, Rosenberg JE, Choueiri TK. Recent progress and pitfalls in testing novel agents in castration-resistant prostate cancer. Eur Urol. 2009;56(4):606–8. Epub 2009 Jul 22.

    PubMed  Google Scholar 

  100. Nilsson S, Franz L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre placebo-controlled phase II study. Lancet Oncol. 2007;8(7):587–94.

    PubMed  CAS  Google Scholar 

  101. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 2000;18:3894–903.

    PubMed  CAS  Google Scholar 

  102. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24(19):3089–94.

    PubMed  CAS  Google Scholar 

  103. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115(16):3670–9.

    PubMed  CAS  Google Scholar 

  104. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, et al. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28(7):1099–105.

    PubMed  CAS  Google Scholar 

  105. Higano CS, Corman JM, Smith DC, Centeno AS, Steidle CP, Gittleman M, et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer. 2008;113:975–84.

    PubMed  CAS  Google Scholar 

  106. Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol. 2008;26:5275–83.

    PubMed  CAS  Google Scholar 

  107. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271:1734–6.

    PubMed  CAS  Google Scholar 

  108. Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2007;13:1810–5.

    PubMed  CAS  Google Scholar 

  109. Beer TM, Slovin SF, Higano CS, Tejwani S, Dorff TB, Stankevich E, et al. Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol. 2008;26:abstract 5004.

    Google Scholar 

  110. Gerritsen W, Van Den Eertwegh AJ, De Gruijl T, Giaccone G, Scheper RJ, Lowy I, et al. A dose-escalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular immunotherapy in combination with a fully human anti-CTLA antibody (MDX-010, ipilimumab) in patients with metastatic hormone-­refractory prostate cancer (mHRPC). J Clin Oncol. 2006;24:abstract 2500.

    Google Scholar 

  111. Harzstark AL, Fong L, Weinberg VK, et al. Final results of a phase I study of CTLA-4 blockade in combination with GM-CSF for matastatic castration resistant prostate cancer (mCRPC). 2010 ASCO annual meeting. 2010:abstract #4689.

    Google Scholar 

  112. Wang Y, Sun Y. Insulin-like growth factor receptor-1 as an anti-cancer target: blocking transformation and inducing apoptosis. Curr Cancer Drug Targets. 2002;2(3):191–207.

    PubMed  CAS  Google Scholar 

  113. Pollak MN, Schernhammer ES, Hankinson SE, et al. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004;4(7):505–18.

    PubMed  CAS  Google Scholar 

  114. Mulvihill MJ, Ji QS, Coate HR, et al. Novel 2-phenylquinolin-7-yl-derived imidazo [1,5-a] pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors. Bioorg Med Chem. 2008;16(3):1359–75.

    PubMed  CAS  Google Scholar 

  115. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst. 2008;94:1099–106.

    Google Scholar 

  116. Hankison SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 1998;351(9113):1393–6.

    Google Scholar 

  117. Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colotectal cancer risk in men and plasma levels of insulin-like growth factor-I receptor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst. 2004;91(7):620–5.

    Google Scholar 

  118. Quin KA, Treston AM, Unsworth EJ, et al. Insulin-like growth factor expression in human cancer cell lines. J Biol Chem. 1996;271(19):11477–83.

    Google Scholar 

  119. Yu H, Spitz MR, Mistry J, et al. Plasma levels of insulin-like frowth factor-I and lung cancer risk: a case–control analysis. J Natl Cancer Inst. 1999;91(2):151–6.

    PubMed  CAS  Google Scholar 

  120. Zhao H, Grossman MR, Spitz MR, et al. Plasma levels of insulin-like growth factor-I and binding protein-3, and their association with bladder cancer. J Urol. 2003;169(2):714–7.

    PubMed  CAS  Google Scholar 

  121. Resnicoff M, Tjuvajev J, Rotman HL, et al. Regression of C6 rat brain tumors by cells expressing an antisense insulin-like growth factor I receptor RNA. J Exp Ther Oncol. 1996;1(6):385–9.

    PubMed  CAS  Google Scholar 

  122. Wang Y, Hailey J, Williams D, et al. Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol Cancer Ther. 2005;4(8):1214–21.

    PubMed  CAS  Google Scholar 

  123. Cohen BD, Baker DA, Soderstrom C, et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res. 2005;11(5):2063–73.

    PubMed  CAS  Google Scholar 

  124. Garber K. IGF-1: old growth factor shines as new drug target. J Natl Cancer Inst. 2005;97(11):790–2.

    PubMed  CAS  Google Scholar 

  125. Sachdev D, Hartell JS, Lee AV, et al. A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J Biol Chem. 2004;279(6):5017–24.

    PubMed  CAS  Google Scholar 

  126. Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363:1346–53.

    PubMed  CAS  Google Scholar 

  127. Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res. 2002;62:2942–50.

    PubMed  CAS  Google Scholar 

  128. Krueckl SL, Sikes RA, Edlund NM, Bell RH, Hurtado-Coll A, Fazli L, et al. Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res. 2004;64:8620–9.

    PubMed  CAS  Google Scholar 

  129. Wu JD, Odman A, Higgins LM, Haugk K, Vessella R, Ludwig DL, et al. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-­independent xenograft human prostate tumors. Clin Cancer Res. 2005;11:3065–74.

    PubMed  CAS  Google Scholar 

  130. Higano C, Alumkal J, Ryan CJ, Yu EY, Beer TM, et al. A phase II study evaluating the efficacy and safety of single agent IMC A12, a monoclonal antibody, against the insulin-like growth factor-1 receptor, as monotherapy in patients with metastatic, asymptomatic castration-resistant prostate cancer. J Clin Oncol. 2009;27:abstract 5142.

    Google Scholar 

  131. Rathkopf DE, Danila DC, Chudow JJ, et al. Anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody cixutumumab plus mammalian target of rapamycin (mTOR) inhibitor temsirolimus in metastatic castration-resistant prostate cancer (CRPC). 2010 ASCO annual meeting. 2010:abstract #TPS242.

    Google Scholar 

  132. Dean JP, Plymate SR, Dalkin BL, et al. Neoadjuvant IMC-A12 and combined androgen deprivation with prostatectomy for high-risk prostate cancer: a phase II trial. 2010 ASCO annual meeting. 2010:abstract #TPS251.

    Google Scholar 

  133. Molife LR, Fong PC, Paccagnella L, Reid AH, Shaw HM, Vidal L, et al. The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. Br J Cancer. 2010;103(3):332–9.

    PubMed  CAS  Google Scholar 

  134. Chi KN, Gleave ME, Fazil L, et al. A phase II study of preoperative figitumumab (F) in patients (PTS) with localized prostate cancer (PCa). J Clin Oncol. 2010;28(15s):abstract 4662.

    Google Scholar 

  135. Friedlander TW, Weinberg VK, Formaker C, et al. The effect of inhibition of the insulin-like growth factor receptor with nordihydroguaiaretic acid on PSA progression: results of a phase II study. 2010 ASCO annual meeting. 2010:abstract #4670.

    Google Scholar 

  136. Vivanco I, Sawyers C. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489–501.

    PubMed  CAS  Google Scholar 

  137. Gera JF, Mellinghoff IK, Shi Y, et al. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol. 2004;279:2737–46.

    CAS  Google Scholar 

  138. Mousses S, Wagner U, Chen Y, Kim JW, Bubendorf L, Bittner M, Pretlow T, Elkahloun AG, Trepel JB, Kallioniemi OP. Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene. 2007;20(41):6718–23.

    Google Scholar 

  139. Wang Y, Mikhailova M, Bose S, Pan CX, de Vere White RW, Ghosh PM. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. Oncogene. 2008;27(56):7106–17.

    PubMed  CAS  Google Scholar 

  140. Yoshimoto M, Cunha IW, Coudry RA, et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer. 2007;97(5):678–85.

    PubMed  CAS  Google Scholar 

  141. Yoshimoto M, Joshua AM, Cunha IW, Coudry RA, Fonseca FP, Ludkovski O, Zielenska M, Soares FA, Squire JA. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol. 2008;21(12):1451–60.

    PubMed  CAS  Google Scholar 

  142. Amato RJ, Jac J, Mohammad T, Saxena S. Pilot study of rapamycin in patients with hormone-refractory prostate cancer. Clin Genitourin Cancer. 2008;6(2):97–102.

    PubMed  CAS  Google Scholar 

  143. Armstrong AJ, Netto GJ, Rudek MA, Halabi S, Wood DP, Creel PA, et al. A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clin Cancer Res. 2010;16(11):3057–66.

    PubMed  CAS  Google Scholar 

  144. Armstrong AJ, Kemeny G, Turnbull JD, et al. Impact of temsirolimus and anti-androgen therapy on circulating tumor cell (CTC) biology in men with castration-resistant metastatic prostate cancer (CRPC): a phase II study. 2010 ASCO annual meeting. 2010:Abstract:TPS249.

    Google Scholar 

  145. Liu X, Gomez-Pinillos A, Ferrari AC. Simultaneous targeting of the androgen receptor and PI3K/mTOR pathway in androgen-­dependent and androgen-independent prostate cancer cells. 2010 ASCO annual meeting. 2010:abstract #e15049.

    Google Scholar 

  146. Pan C, Ghosh P, Suga JM, et al. Encouraging activity of bicalutamide and everolimus in castration-resistant prostate cancer (CRPC): early results from a phase I/II clinical trial. 2010 ASCO annual meeting. 2010:abstract #e15131.

    Google Scholar 

  147. Buckle GC, Werner L, Oh WK, et al. Phase II troal of RAD001 (R) and bicalutamide (B) for castration-resistant prostate cancer (CRPC). 2010 ASCO annual meeting. 2010:abstract #4660.

    Google Scholar 

  148. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of akt signaling through an IGF-1R-dependent mechanism. Oncogene. 2007;26:1932–40.

    PubMed  CAS  Google Scholar 

  149. Yap TA, Patnaik A, Fearen I, et al. First-in-class phase I trial of a selective Akt inhibitor, MK2206 (MK), evaluatingalternate dat (QOD) and once weekly (QW) doses in advanced cancer patients (pts) with evidence of target modulation and antitumor activity. 2010 ASCO annual meeting. 2010:abstract #3009.

    Google Scholar 

  150. Tolcher AW, Yap TA, Fearen I, et al. A phase I study of MK-2206, an oral potent allosteric akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST). 2009 ASCO Annual Meeting. 2009:abstract #3503.

    Google Scholar 

  151. Brana I, LoRusso P, Baselga J, et al. A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies. 2010 ASCO annual meeting. 2010:abstract #3030.

    Google Scholar 

  152. Banerji U. Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res. 2009;15:9–14.

    PubMed  CAS  Google Scholar 

  153. Edwards A, Li J, Atadja P, Bhalla K, Haura EB. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. Mol Cancer Ther. 2007;6:2515–24.

    PubMed  CAS  Google Scholar 

  154. Pratt WB, Galigniana MD, Morishima Y, Murphy PJ. Role of molecular chaperones in steroid receptor action. Essays Biochem. 2004;40:41–58.

    PubMed  CAS  Google Scholar 

  155. Marrocco DL, Tilley WD, Bianco-Miotto T, Evdokiou A, Scher HI, Rifkind RA, et al. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther. 2007;6:51–60.

    PubMed  CAS  Google Scholar 

  156. Welsbie DS, Xu J, Chen Y, Borsu L, Scher HI, Rosen N, et al. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res. 2009;69:958–66.

    PubMed  CAS  Google Scholar 

  157. Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S, Skotheim RI, et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res. 2006;66:10242–6.

    PubMed  CAS  Google Scholar 

  158. Bjorkman M, Iljin K, Halonen P, Sara H, Kaivanto E, Nees M, et al. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer. Int J Cancer. 2008;123:2774–81.

    PubMed  CAS  Google Scholar 

  159. Heath EI, Hillman DW, Vaishampayan U, Sheng S, Sarkar F, Harper F, et al. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res. 2008;14:7940–6.

    PubMed  CAS  Google Scholar 

  160. Hussain M, Dunn R, Rathkopf D, Stadler W, Wilding G, Smith DC, et al. Suberoylanilide hydroxamic acid (vorinostat) post chemotherapy in hormone refractory prostate cancer (HRPC) patients (pts): a phase II trial by the prostate cancer clinical trials consortium (NCI 6862). J Clin Oncol. 2007;25:5132.

    Google Scholar 

  161. Zoubeidi A, Chi K, Gleave M. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res. 2010;16(4):1088–93.

    PubMed  CAS  Google Scholar 

  162. Humphreys DT, Carver JA, Easterbrook-Smith SB, Wilson MR. Clusterin has chaperone-like activity similar to that of small heat shock proteins. J Biol Chem. 1999;274:6875–81.

    PubMed  CAS  Google Scholar 

  163. Zhang H, Kim JK, Edwards CA, Xu Z, Taichman R, Wang CY. Clusterin inhibits apoptosis by interacting with activated bax. Nat Cell Biol. 2005;7:909–15.

    PubMed  CAS  Google Scholar 

  164. Ammar H, Closset JL. Clusterin activates survival through the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem. 2008;283:12851–61.

    PubMed  CAS  Google Scholar 

  165. Gleave M, Chi KN. Knock-down of the cytoprotective gene, clusterin, to enhance hormone and chemosensitivity in prostate and other cancers. Ann N Y Acad Sci. 2005;1058:1–15.

    PubMed  CAS  Google Scholar 

  166. Miayake H, Tolcher A, Gleave ME. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J Natl Cancer Inst. 2000;92:34–41.

    PubMed  CAS  Google Scholar 

  167. July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate. 2002;50:179–88.

    PubMed  CAS  Google Scholar 

  168. Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst. 2005;97:1287–96.

    PubMed  CAS  Google Scholar 

  169. Chi KN, Siu LL, Hirte H, Hotte SJ, Knox J, Kollmansberger C, et al. A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res. 2008;14:833–9.

    PubMed  CAS  Google Scholar 

  170. Saad F, Hotte SJ, North SA, Eigl BJ, Chi KN, Czaykowski P, et al. A phase II randomized study of custirsen (OGX-011) combination therapy in patients with poor-risk hormone refractory prostate cancer (HRPC) who relapsed on or within six months of 1st-line docetaxel therapy. J Clin Oncol. 2008;26:abstract 5002.

    Google Scholar 

  171. Chi KN, Hotte SJ, Yu E, Eigl BJ, Tannock I, Saad F, et al. A randomized phase II study of OGX-011 in combination with docetaxel and prednisone or docetaxel and prednisone alone in patients with metastatic hormone refractory prostate cancer (HRPC). J Clin Oncol. 2007;25:abstract 5069.

    Google Scholar 

  172. Chi KN, Hotte SJ, Yu E, Tu D, Eigl B, et al. Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2009;27:abstract 5012.

    Google Scholar 

  173. Zoubeidi A, Zardan A, Beraldi E, Fazli L, Sowery R, Rennie P, et al. Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res. 2007;67(21):10455–65.

    PubMed  CAS  Google Scholar 

  174. Hotte SJ, Yu EY, Hirte HW, et al. Phase I trial of OGX-427, a 2′methoxyethyl antisense oligonucleotide (ASO), against heat shock protein 27 (Hsp27): Final results. 2010 ASCO annual meeting. 2010:abstract 3077.

    Google Scholar 

  175. Huss WJ, Hanrahan CF, Barrios RJ, Simons JW, Greenberg NM. Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res. 2001;61:2736–43.

    PubMed  CAS  Google Scholar 

  176. George DJ, Halabi S, Shepard TF, Vogelzang NJ, Hayes DF, Small EJ, et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on cancer and leukemia group B 9480. Clin Cancer Res. 2001;7:1932–6.

    PubMed  CAS  Google Scholar 

  177. Melnyk O, Zimmerman M, Kim KJ, Shuman M. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. J Urol. 1999;161:960–3.

    PubMed  CAS  Google Scholar 

  178. Jain RK, Tong RT, Munn LL. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res. 2007;67:2729–35.

    PubMed  CAS  Google Scholar 

  179. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349(5):427–34.

    PubMed  CAS  Google Scholar 

  180. Picus J, Halabi S, Rini B, Vogelzang N, Whang Y, Kaplan E, et al. The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): initial results of CALGB 90006. Proc Am Soc Clin Oncol. 2003;22:abstract 1578.

    Google Scholar 

  181. Kelly WK, Halabi S, Carducci MA, et al. A randomized, double-blind, placebo-controlled phase III trial compating docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401. 2010 ASCO annual meeting. 2010:abstract #LBA4511.

    Google Scholar 

  182. Gross ME, Soscia J, Sakowsky S, Castellanos O, Agus DB. Phase I trial of RAD001, bevacizumab, and docetaxel for castration-resistant prostate cancer (CRPC). J Clin Oncol. 2009;27:abstract 5154.

    Google Scholar 

  183. Vaishampayan UN, Heilbrun LK, Heath EI, Smith DW, Dickow B, et al. Phase II trial of bevacizumab and oral satraplatin and prednisone in docetaxel pretreated metastatic castrate resistant prostate cancer. J Clin Oncol. 2009;27:abstract e16028.

    Google Scholar 

  184. Verheul HM, Hammers H, van Erp K, Wei Y, Sanni T, Salumbides B, et al. Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin Cancer Res. 2007;13:4201–8.

    PubMed  CAS  Google Scholar 

  185. Isambert N, Freyer G, Zanetta S, Falandry C, Soussan Lazard K, Fumoleau P. A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel (D) in patients (pts) with advanced solid tumors: preliminary results. J Clin Oncol. 2008;26:abstract 3599.

    Google Scholar 

  186. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–24.

    PubMed  CAS  Google Scholar 

  187. Sonpavde G, Periman PO, Bernold D, et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol. 2010;21(2):319–24.

    PubMed  CAS  Google Scholar 

  188. Zurita AJ, Liu G, Hutson T, Kozloff M, Shore N, et al. Sunitinib in combination with docetaxel and prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol. 2009;27:abstract 5166.

    Google Scholar 

  189. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–34.

    PubMed  CAS  Google Scholar 

  190. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.

    PubMed  CAS  Google Scholar 

  191. Chi KN, Ellard SL, Hotte SJ, Czaykowski P, Moore M, Ruether JD, Schell AJ, Taylor S, Hansen C, Gauthier I, Walsh W, Seymour L. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol. 2008;19(4):746–51.

    PubMed  CAS  Google Scholar 

  192. Aragon-Ching JB, Jain L, Gulley JL, Arlen PM, Wright JJ, Steinberg SM, Draper D, Venitz J, Jones E, Chen CC, Figg WD, Dahut WL. Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int. 2009;103(12):1636–40.

    PubMed  CAS  Google Scholar 

  193. Mardjuadi F, Medioni J, Kerger J, Canon JL, Duck L, et al. A phase I study of sorafenib in association with docetaxel-prednisone in chemonaive metastatic castration-resistant prostate cancer. J Clin Oncol. 2009;27:abstract 5153.

    Google Scholar 

  194. Nabhan C, Tolzein K, Lestingi TM, Galvez A, Bitran JD, et al. Effect of sorafenib on chemotherapy resistance and refractoriness in castration-resistant prostate cancer. J Clin Oncol. 2009;27:abstract e16105.

    Google Scholar 

  195. Karakunnel JJ, Gulley JL, Arlen P, Mulquin M, Wright J, et al. Cediranib (AZD2171) in docetaxel-resistant, castration-resistant prostate cancer. J Clin Oncol. 2009;27:abstract 5141.

    Google Scholar 

  196. Zhang S, Zhau HE, Osunkoya AO, Iqbal S, Yang X, Fan S, et al. Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells. Mol Cancer. 2010;9:9.

    PubMed  Google Scholar 

  197. Knudsen BS, Gmyrek GA, Inra J, Scherr DS, Vaughan ED, Nanus DM, et al. High expression of the met receptor in prostate cancer metastasis to bone. Urology. 2002;60(6):1113–7.

    PubMed  Google Scholar 

  198. Hussain M, Smith MR, Sweeney C, et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer 0mCRPC): results from a phase II randomized discontinuation trial. J Clin Oncol. 2010;29(suppl):abstr 4516.

    Google Scholar 

  199. Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res. 2001;7(7):1888–93.

    PubMed  CAS  Google Scholar 

  200. Figg WD, Arlen P, Gulley J, Fernandez P, Noone M, Fedenko K, et al. A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Semin Oncol. 2001;28(4 Suppl 15):62–6.

    PubMed  CAS  Google Scholar 

  201. Drake MJ, Robson W, Mehta P, Schofield I, Neal DE, Leung HY. An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer. 2003;88(6):822–7.

    PubMed  CAS  Google Scholar 

  202. Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol. 2004;22(13):2532–9.

    PubMed  CAS  Google Scholar 

  203. Lentzsch S, LeBlanc R, Podar K, Davies F, Lin B, Hideshima T, et al. Immunomodulatory analogs of thalidomide inhibit growth of hs sultan cells and angiogenesis in vivo. Leukemia. 2003;17(1):41–4.

    PubMed  CAS  Google Scholar 

  204. Lu L, Payvandi F, Wu L, Zhang LH, Hariri RJ, Man HW, et al. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res. 2009;77(2):78–86.

    PubMed  CAS  Google Scholar 

  205. Zhu D, Corral LG, Fleming YW, Stein B. Immunomodulatory drugs revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother. 2008;57(12):1849–59.

    PubMed  CAS  Google Scholar 

  206. Dahut WL, Aragon-Ching JB, Woo S, Tohnya TM, Gulley JL, Arlen PM, et al. Phase I study of oral lenalidomide in patients with refractory metastatic cancer. J Clin Pharmacol. 2009;49(6):650–60.

    PubMed  CAS  Google Scholar 

  207. Pili R, Haggman M, Stadler WM, et al. A randomized, multicenter, international phase II study of tasquinimod in chemotherapy naive patients with metastatic castrate-resistant prostate cancer (CRPC). 2010 ASCO annual meeting. 2010:abstract #4510.

    Google Scholar 

  208. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002;2(10):727–39.

    PubMed  CAS  Google Scholar 

  209. Verheul HM, Salumbides B, Van Erp K, Hammers H, Qian DZ, Sanni T, et al. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Clin Cancer Res. 2008;14(11):3589–97.

    PubMed  CAS  Google Scholar 

  210. Brahimi-Horn MC, Pouyssegur J. The hypoxia-inducible factor and tumor progression along the angiogenic pathway. Int Rev Cytol. 2005;242:157–213.

    PubMed  CAS  Google Scholar 

  211. Quintero M, Mackenzie N, Brennan PA. Hypoxia-inducible factor 1 (HIF-1) in cancer. Eur J Surg Oncol. 2004;30(5):465–8.

    PubMed  CAS  Google Scholar 

  212. Hellebrekers DM, Melotte V, Vire E, Langenkamp E, Molema G, Fuks F, et al. Identification of epigenetically silenced genes in tumor endothelial cells. Cancer Res. 2007;67(9):4138–48.

    PubMed  CAS  Google Scholar 

  213. Liu T, Liu PY, Tee AE, Haber M, Norris MD, Gleave ME, et al. Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors. Eur J Cancer. 2009;45(10):1846–54.

    PubMed  CAS  Google Scholar 

  214. Carey LA, Sharpless NE. PARP and cancer – if it’s broke, don’t fix it. N Engl J Med. 2011;364(3):277–9. Epub 2011 Jan 5.

    PubMed  CAS  Google Scholar 

  215. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–21.

    PubMed  CAS  Google Scholar 

  216. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123–34.

    PubMed  CAS  Google Scholar 

  217. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010;28(15):2512–9.

    PubMed  CAS  Google Scholar 

  218. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006;66(16):8109–15.

    PubMed  CAS  Google Scholar 

  219. Turner N, Tutt A, Ashworth A. Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer. 2004;4(10):814–9.

    PubMed  CAS  Google Scholar 

  220. Sircar K, Yoshimoto M, Monzon FA, Koumakpayi IH, Katz RL, Khanna A, et al. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol. 2009;218(4):505–13.

    PubMed  CAS  Google Scholar 

  221. Verhagen PC, van Duijn PW, Hermans KG, Looijenga LH, van Gurp RJ, Stoop H, et al. The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion. J Pathol. 2006;208(5):699–707.

    PubMed  CAS  Google Scholar 

  222. Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med. 2009;1(6–7):315–22.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, British Columbia Cancer Agency, Vancouver Cancer Centre, 600 W10th Ave, Vancouver, BC, V5Z 4E6, Canada

    Robyn J. Macfarlane B.Sc., M.D. (FRCPC) & Kim N. Chi

  2. Departments of Urology and Surgery, Royal Melbourne Hospital and University of Melbourne, Grattan Street, Parkville, Melbourne, VIC, 3050, Australia

    Chris Hovens & Niall M. Corcoran Ph.D., FRACS (Urol)

  3. Australian Prostate Cancer Centre@Epworth, Melbourne, VIC, Australia

    Chris Hovens & Niall M. Corcoran Ph.D., FRACS (Urol)

  4. Departments of Medicine and Urological Sciences, University of British Columbia, Vancouver, BC, Canada

    Kim N. Chi

Authors
  1. Robyn J. Macfarlane B.Sc., M.D. (FRCPC)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chris Hovens
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Niall M. Corcoran Ph.D., FRACS (Urol)
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kim N. Chi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robyn J. Macfarlane B.Sc., M.D. (FRCPC) .

Editor information

Editors and Affiliations

  1. New York Presbyterian Hospital, Brady Urologic Health Center, Weill Cornell Medical Center, East 68th Street 525, New York, 10021, New York, USA

    Ashutosh Tewari

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag London

About this chapter

Cite this chapter

Macfarlane, R.J., Hovens, C., Corcoran, N.M., Chi, K.N. (2013). Chemotherapy and Novel Systemic Approaches in the Treatment of Metastatic Castration Resistant Prostate Cancer. In: Tewari, A. (eds) Prostate Cancer: A Comprehensive Perspective. Springer, London. https://doi.org/10.1007/978-1-4471-2864-9_76

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-2864-9_76

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-2863-2

  • Online ISBN: 978-1-4471-2864-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation